Piper Sandler Initiates Coverage On Jasper Therapeutics with Overweight Rating, Announces Price Target of $2
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsInitiationPrice Target
Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.
Piper Sandler analyst Biren Amin initiates coverage on Jasper Therapeutics (NASDAQ:JSPR) with a Overweight rating and announces Price Target of $2.